BioRestorative TherapiesBRTX
BRTX
About: BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Employees: 11
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
24% more capital invested
Capital invested by funds: $406K [Q4 2024] → $502K (+$95.8K) [Q1 2025]
0.02% less ownership
Funds ownership: 4.1% [Q4 2024] → 4.07% (-0.02%) [Q1 2025]
7% less funds holding
Funds holding: 15 [Q4 2024] → 14 (-1) [Q1 2025]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Research analyst outlook
We haven’t received any recent analyst ratings for BRTX.
Financial journalist opinion
Neutral
GlobeNewsWire
2 days ago
BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease
– The International Society for Stem Cell Research (“ISSCR”) 2025 Annual Meeting is the world's foremost gathering of stem cell and regenerative medicine leaders –
Neutral
GlobeNewsWire
6 days ago
BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025
– New blinded safety and efficacy data from 30 patients in ongoing Phase 2 trial to be unveiled June 13, 2025 – – ISSCR 2025 is the premier global event for stem cell research, drawing nearly 4,000 leaders from academia, biotech, and pharma – – BioRestorative to release new clinical data to the public prior to market open on June 13th – MELVILLE, N.Y., June 09, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical-stage regenerative medicine company developing stem cell-based therapies for serious musculoskeletal conditions, today announced that new preliminary, blinded clinical data from 30 patients enrolled in its ongoing Phase 2 trial of BRTX-100 for the treatment of chronic lumbar disc disease (cLDD) will be presented at the prestigious International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting, held June 11–14, 2025, in Hong Kong.
Neutral
Seeking Alpha
1 month ago
BioRestorative Therapies, Inc. (BRTX) Q1 2025 Earnings Call Transcript
BioRestorative Therapies, Inc. (NASDAQ:BRTX ) Q1 2025 Earnings Call May 14, 2025 4:30 PM ET Company Participants Stephen Kilmer - Investor Relations Lance Alstodt - Chairman and Chief Executive Officer Francisco Silva - Vice President, Research and Development Robert Kristal - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH Jason McCarthy - Maxim Group Operator Good afternoon, everyone and welcome to the BioRestorative Therapies First Quarter 2025 Investor Call. [Operator Instructions] Please note, this conference is being recorded.
Negative
Zacks Investment Research
1 month ago
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates
Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.53 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
MELVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that preliminary 26-, 52- and 104-week blinded preliminary data from the first 15 patients with chronic lumbar disc disease (“cLDD”) enrolled in the ongoing Phase 2 clinical trial of BRTX-100 was recently presented by Francisco Silva, Vice President of Research and Development, at the International Society for Cell & Gene Therapy (“ISCT”) 2025 Annual Meeting.
Neutral
GlobeNewsWire
1 month ago
BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025
MELVILLE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its first quarter 2025 financial results after market close on Wednesday, May 14, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update.
Neutral
GlobeNewsWire
1 month ago
BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025
MELVILLE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Vice President of Research and Development, Francisco Silva, will present an update on its ongoing Phase 2 clinical trial of BRTX-100 in chronic lumbar disc disease (cLDD) at the International Society for Cell & Gene Therapy (“ISCT”) 2025 Annual Meeting, taking place May 7 - 10, 2025 in New Orleans, LA.
Neutral
GlobeNewsWire
2 months ago
BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities
MELVILLE, N.Y., April 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Chief Executive Officer, Lance Alstodt, will be interviewed during the Benzinga All-Access Show today, Tuesday, April 15, 2025, at 10:50 a.m. Eastern time.
Neutral
GlobeNewsWire
2 months ago
BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States
MELVILLE, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to confirm that it currently faces no material exposure to newly imposed U.S. tariffs.
Neutral
Seeking Alpha
2 months ago
BioRestorative Therapies, Inc. (BRTX) Q4 2024 Earnings Call Transcript
BioRestorative Therapies, Inc. (NASDAQ:BRTX ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Lance Alstodt – Chairman and Chief Executive Officer Rob Kristal – Chief Financial Officer Francisco Silva – Vice President-Research and Development Conference Call Participants Michael Okunewitch – Maxim Group Elemer Piros – Rodman & Renshaw Operator Good afternoon, everyone, and welcome to the BioRestorative Therapies 2024 Results Conference Call. At this time all participants are in a listen-only mode [Operator Instructions] Please note this conference is being recorded.
Charts implemented using Lightweight Charts™